18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): results from a randomised clinical trial.

[1]  I. Lax,et al.  The HILUS-trial - a prospective Nordic multi-center phase II study of ultra-central lung tumors treated with stereotactic body radiotherapy. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  P. Krawczyk,et al.  Molecular and Clinical Premises for the Combination Therapy Consisting of Radiochemotherapy and Immunotherapy in Non-Small Cell Lung Cancer Patients , 2021, Cancers.

[3]  P. D. de Jong,et al.  Prognostic factors for overall survival of stage III non-small cell lung cancer patients on computed tomography: a systematic review and meta-analysis. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  Joseph O. Deasy,et al.  Modeling the Impact of Cardiopulmonary Irradiation on Overall Survival in NRG Oncology Trial RTOG 0617 , 2020, Clinical Cancer Research.

[5]  K. Forster,et al.  Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Louie,et al.  Pathologic response after modern radiotherapy for non-small cell lung cancer. , 2019, Translational lung cancer research.

[7]  J. Aerts,et al.  Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.

[8]  Hui Yang,et al.  Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges , 2019, Precision clinical medicine.

[9]  J. Sonke,et al.  The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial). , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  J. Wynne,et al.  Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation , 2018, Front. Oncol..

[11]  Rob H N Tijssen,et al.  Magnetic resonance imaging in precision radiation therapy for lung cancer. , 2017, Translational lung cancer research.

[12]  F. Salvi,et al.  Radiological differential diagnosis between fibrosis and recurrence after stereotactic body radiation therapy (SBRT) in early stage non-small cell lung cancer (NSCLC). , 2017, Translational lung cancer research.

[13]  S. Formenti,et al.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. , 2017, The Lancet. Oncology.

[14]  Jan-Jakob Sonke,et al.  Modeling the Cellular Response of Lung Cancer to Radiation Therapy for a Broad Range of Fractionation Schedules , 2017, Clinical Cancer Research.

[15]  J. Jett,et al.  Long‐Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance) , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  R. Govindan,et al.  PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Senan,et al.  Outcomes of Hypofractionated High‐Dose Radiotherapy in Poor‐Risk Patients with “Ultracentral” Non–Small Cell Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  J. Sonke,et al.  Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  L. Thiberville,et al.  Areas of High 18F-FDG Uptake on Preradiotherapy PET/CT Identify Preferential Sites of Local Relapse After Chemoradiotherapy for Non–Small Cell Lung Cancer , 2015, The Journal of Nuclear Medicine.

[20]  W. Curran,et al.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.

[21]  Jan-Jakob Sonke,et al.  The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  Benjamin Movsas,et al.  Defining Local-Regional Control and Its Importance in Locally Advanced Non-small Cell Lung Carcinoma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  Benjamin Movsas,et al.  Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. , 2012, International journal of radiation oncology, biology, physics.

[24]  Jose Belderbos,et al.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Lambin,et al.  Can we optimize chemo-radiation and surgery in locally advanced stage III non-small cell lung cancer based on evidence from randomized clinical trials? A hypothesis-generating study. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  P. Lambin,et al.  Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  W. Oyen,et al.  The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  Philippe Lambin,et al.  Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study. , 2008, International journal of radiation oncology, biology, physics.

[29]  G. Giaccone,et al.  Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). , 2007, European journal of cancer.

[30]  W. Curran,et al.  Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. , 2005, International journal of radiation oncology, biology, physics.

[31]  C. Ling,et al.  Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.

[32]  R. A’Hern.  Sample size tables for exact single‐stage phase II designs , 2001, Statistics in medicine.

[33]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .